RNA Editing Machinery & Metabolic Oncology: High-Purity Reagents for A1CF-Targeted Drug Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for A1CF drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | A1CF Recombinant Protein (Full-Length) RRM domains intact. Sequence Verified, >95% purity by SDS-PAGE. Endotoxin <1 EU/µg. Suitable for RNA EMSA and PPI studies. |
View A1CF Products |
| Gene Delivery | A1CF Lentivirus Particles (ORF) CMV promoter, Puromycin selection. For stable cell line construction in hepatic or colorectal models. |
View A1CF Products |
| Benchmark Ab | Anti-A1CF Monoclonal Antibody (Clone 4F8) Recombinant rabbit mAb. Validated for WB/IP. Sequence verified heavy/light chains. |
View A1CF Products |
| Validator | A1CF siRNA Set (3 unique targets) Guaranteed >70% knockdown efficiency. Includes non-targeting negative control. |
View A1CF Products |
| Complex Partner | APOBEC1 Cytidine deaminase binding partner. Required for functional editing complex reconstitution assays. |
View APOBEC1 Products |
| Pathway Substrate | APOB (Apolipoprotein B) Downstream target of A1CF-mediated RNA editing machinery. For substrate tracking assays. |
View APOB Products |
| Paralog Control | SYNCRIP (hnRNP Q) RRM-containing RNA-binding protein for selectivity counter-screening. |
View SYNCRIP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| RNA-binding specificity (RRM domain fidelity) | Sequence-verified full-length protein with intact RNA Recognition Motifs; Low endotoxin prevents cellular stress artifacts |
| A1CF/APOBEC1 heterodimer reconstitution | Matched high-purity protein pair available (A1CF + APOBEC1); Consistent lot-to-lot activity for SPR/AlphaScreen |
| Off-target RRM protein selectivity | SYNCRIP/hnRNP paralog proteins available for counter-screening; Mass spec verified identity |
| Cellular validation of RNA editing inhibition | Validated siRNA set + Lentivirus overexpression system for bidirectional modulation |
Live A1CF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic potential of A1CF (APOBEC1 Complementation Factor) is emerging at the intersection of metabolic disease and oncology. As an essential RNA-binding cofactor for APOBEC1-mediated RNA editing, A1CF controls the hepatic production of apoB-48 versus apoB-100, linking it to lipid metabolism. Parallel research implicates A1CF in hepatocellular carcinoma (HCC) and colorectal cancer proliferation through alternative RNA processing mechanisms.
Current R&D focuses on:
- Metabolic modulation: Small molecules disrupting the A1CF-RNA interface to alter lipoprotein profiles
- Oncology targets: siRNA and ASO approaches for liver and gastrointestinal malignancies
- Complex biophysics: Structural studies requiring high-quality recombinant proteins for cryo-EM/X-ray crystallography
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| RNA-targeted Small Molecule | Academic consortia, Emerging biotech | Hyperlipidemia, NAFLD | RNA EMSA competition assays (Need RNase-free high-purity A1CF) |
| siRNA / ASO | RNA therapeutics specialists | HCC, CRC | Knockdown validation (Need validated siRNA + antibody combo) |
| Biochemical Inhibitor | Metabolic disease-focused pharma | Dyslipidemia | A1CF/APOBEC1 PPI disruption assays (Need heterodimer protein pair) |
| PROTAC / Degrader | Targeted protein degradation platforms | Oncology | Ternary complex formation (Need high-quality antigen for pulldown) |
Target ID
GM-IP7876
Target